Squamous Cell CarcTumorUndergone limited resectionLUADPrognosticOncogenicTumoursHistologySCLCAcinarPredominantRecurrenceSurvivalPatientsBreast CancerMolecularTherapiesCasesAccountsTypesRiskStandardFigureYearsPredominant histologicalSquamous cell carcinomasCancersLarge cell carcinomaCarcinomasHeterogeneousTumorsBiomarkersUnclearGenesIncidenceMethodsMortalityTherapeuticOutcomesProgressionMetastasisInvasionCarcinogensSignificantlyCellsSmallStageStudyApproximatelyExpressionSystemDisease
Squamous Cell Carc4
- EML4-ALK (+) lung cancers Acinar predominant adenocarcinoma and crizotinib Signet ring cell adenocarcinoma and crizotinib Papillary adenocarcinoma BAC with EGFR (+) Squamous cell carcinoma (cisplatinum/gemcitabine) Squamous cell carcinoma (no bevacizumab/anti-VEGF in cavitary or in near large vessels Vincent MD (August 2009). (wikipedia.org)
- We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. (frontiersin.org)
- Primary tumor tissues of lung adenocarcinoma (ADC) ( n = 26) and squamous cell carcinoma (SQCC) ( n = 18) obtained from surgery were assigned to subgroups according to the patient's smoking status. (biomedcentral.com)
- Broadly speaking, the main subtypes are pulmonary adenocarcinoma, squamous cell carcinoma (SCC) and large cell carcinoma. (amegroups.org)
Tumor7
- Rational stratification under the HOHMS paradigm uses a combination of histological criteria and molecular characteristics of the tumor. (wikipedia.org)
- Histological stratification should be based on subtypes recognized in the 2004 revision of the World Health Organization (WHO) lung tumor typing system. (wikipedia.org)
- OBJECTIVES: We aimed to assess the predictive value of the total metabolic tumor burden prior to treatment in patients with advanced non-small-cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). (bvsalud.org)
- Lasp1 (LIM and SH3 domain protein 1) promotes tumor proliferation and invasion in multiple cancer entities including non-small cell lung cancer (NSCLC). (oncotarget.com)
- In conclusion, Lasp1 facilitated tumor proliferation and invasion of NSCLC through directly binding to FAK and enhancing the phosphorylation of FAK (Tyr397) and AKT (Ser473). (oncotarget.com)
- Previous studies had confirmed that Lasp1 was significantly overexpressed in multiple malignant tumors including non-small-cell lung cancer (NSCLC) and enhanced tumor proliferation, invasion and metastasis [ 7 - 13 ]. (oncotarget.com)
- There was no clear correlation between tumor size, TDR, and Noguchi subtype. (iaslc.org)
Undergone limited resection2
- To seek optimal surgical procedure for early stage lung cancer, we carried out retrospective analyses of 2122 patients who had undergone limited resection for c-T1N0M0 NSCLC from 26 institutions of Japanese association for chest surgery. (iaslc.org)
- Presence of MIP subtype is an independent risk factor for local recurrence only for patients who have undergone limited resection, regardless of predominant histologic subtype ( 11 ). (amegroups.org)
LUAD3
- The current study aims to construct a robust ferroptosis-related lncRNAs signature to increase the predicted value of lung adenocarcinoma (LUAD) by bioinformatics analysis. (researchsquare.com)
- However, the underlying functions of STARDs in lung adenocarcinoma (LUAD) have not been clarified yet. (medsci.org)
- Non-small cell lung cancer (NSCLC) accounts for 85-90% of cases, while lung adenocarcinoma (LUAD) is the most common subtype [ 2 ]. (medsci.org)
Prognostic3
- Optimal management of NSCLC now requires that tumours be screened for a range of predictive and prognostic biomarkers that help to predict sensitivity to targeted therapy and estimate prognosis respectively ( 17 ). (amegroups.org)
- Although it has been shown that histologic subtypes can be used to stratify surgically resected patients into prognostic groups, its value in determining the survival benefit of chemotherapy has yet to be established. (amegroups.org)
- Prognostic value of each subtype was investigated by comparing outcomes between the adjuvant chemotherapy arm and the no-chemotherapy arm. (amegroups.org)
Oncogenic2
- In this review, we will examine the major subtypes of oncogenic drivers behind NSCLC as well as the development of targeted agents available to treat them both now and in the foreseeable future. (amegroups.org)
- Up to 60% of lung adenocarcinoma and up to 50-80% of SCC have a known oncogenic driver mutation ( Figure 1 ) ( 18 , 19 ). (amegroups.org)
Tumours2
- Another change is the subclassification of adenocarcinoma: the definition of bronchioalveolar carcinoma has been restricted to noninvasive tumours. (ersjournals.com)
- Most of this classification is based on the histological characteristics of tumours seen in surgical or needle biopsy, and is primarily based on light microscopy, although immunohistochemistry and electron microscopy findings are provided when necessary. (ersjournals.com)
Histology3
- NSCLC should now be further sub-classified by histology and driver mutation if one is known or present. (amegroups.org)
- This distinction alone allows for a more tailored selection of cytotoxic chemotherapy in advanced NSCLC without a driver mutation, as seen with enhanced efficacy with pemetrexed in adenocarcinoma ( 14 , 15 ) or the toxicity concerns of bevacizumab in patients with squamous histology ( 16 ). (amegroups.org)
- Histology of each case was reviewed according to the IASLC/ATS/ERS classification and stratified based on predominant histologic subtype. (amegroups.org)
SCLC5
- Early studies suggested that patients with SCLC fared better when treated with chemotherapy and/or radiation than when treated surgically, while non-small cell lung carcinoma (NSCLC) patients generally did better after surgery, and usually did not respond well to chemoradiation. (wikipedia.org)
- SCLC vs. NSCLC), remained the standard for approximately 30-40 years. (wikipedia.org)
- Although these new therapies have had little impact on the treatment of SCLC, some very promising results have been obtained in certain histiological types and subtypes of NSCLC's. (wikipedia.org)
- Lung cancers are histologically classified as Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC). (frontiersin.org)
- However, these results appear to be primarily applicable to NSCLC cases and the strategies for SCLC diagnoses are limited to biopsy, an invasive procedure at times impacted by tissue of poor quality or quantity ( 4 , 5 ). (frontiersin.org)
Acinar2
- Adenocarcinomas: EGFR Mutations K-ras Mutations EML4-ALK Fusions and Mutations Signet ring cell Acinar Papillary Micropapillary Squamous cell carcinomas: Small cell, poorly differentiated Basaloid Large cell carcinomas: Undifferentiated Lymphoepithelioma-like Rhabdoid phenotype Other NSCLC's: Clear cell variants Giant cell carcinomas HOHMS applied to certain lung cancer variants Undifferentiated large cell lung cancer has been shown to be particularly responsive to pemetrexed. (wikipedia.org)
- In 2011, the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) recommended a new classification system to characterize invasive lung ADC based on predominant histologic subtype [lepidic (LEP), acinar (ACN), papillary (PAP), solid (SOL), and micropapillary (MIP)] with presence of each histologic subtype reported in 5% increments ( 6 ). (amegroups.org)
Predominant2
- It has been shown that predominant subtypes are associated with survival outcomes in patients with early-stage lung ADC ( 8 , 9 ). (amegroups.org)
- 0.01) compared with other subtype predominant groups. (amegroups.org)
Recurrence2
- Hence, predicting the postoperative recurrence risk in individual NSCLC patients who are smokers will contribute to developing a qualified postoperative therapeutic strategy. (biomedcentral.com)
- Therefore, identifying novel and objective biomarkers that reflect postoperative recurrence risk in smokers NSCLC patients is needed. (biomedcentral.com)
Survival3
- The "HOHMS Paradigm" posits that treatment regimens for lung cancer patients should be based on a high level of histological and molecular stratification to maximize response rates and survival prolongation, and minimize toxicity. (wikipedia.org)
- It has been seen that ALDH1 expression in non-small cell lung cancer (NSCLC) and the presence of marker was linked to a more tumorigenic potential in the in vivo assessment and shorter disease-free survival in NSCLC patients with platinum treatment. (ijpmonline.org)
- Although advanced treatments including targeted therapy and immunotherapy have developed, such as Crizotinib, Osimertinib, Pembrolizumab, and Atezolizumab, the 5-year overall survival rate of patients with NSCLC is still less than 20% [ 2 ]. (medsci.org)
Patients7
- This "traditional" paradigm, wherein treatment options for lung cancer patients were based on histological stratification into two highly heterogeneous groups (i.e. (wikipedia.org)
- METHODS: Pre-treatment 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (PET/CT) scans performed in two consecutive years for staging in adult patients with confirmed NSCLC were considered. (bvsalud.org)
- RESULTS: A total of 125 NSCLC patients were included. (bvsalud.org)
- Lasp1 may be a novel therapeutic target in the treatment of NSCLC patients. (oncotarget.com)
- From the abstract: 'Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). (cdc.gov)
- Lobectomy remains the standard treatment for early-stage non-small cell lung cancer (NSCLC).In practice, however, sublobar resection has been selectively offered for patients with clinical Stage IA NSCLC as curative treatment. (iaslc.org)
- This retrospective study evaluated patients with stage I-III NSCLC selected from the LACE-Bio database composed of 4 large cohorts-this includes the International Adjuvant Lung Cancer Trial ( 13 ), JBR.10 ( 14 ), Adjuvant Navelbine International Trialist Association ( 15 ), and Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology ( 16 ). (amegroups.org)
Breast Cancer1
- However, the role of PTEN alterations in north Indian breast cancer has not been explored especially in defining a group with distinct histological factors. (cancerindex.org)
Molecular2
- Over the last decade, molecular translational research advances have heralded major breakthroughs in the understanding, diagnosis and management of lung cancer, particularly for the more common (~80%) non-small cell lung cancer (NSCLC). (amegroups.org)
- It is now accepted that NSCLC is not a singular entity but is in fact multiple pathologies with unique molecular signatures that we are only beginning to unravel and understand ( 11 - 13 ). (amegroups.org)
Therapies1
- In this review, we will examine the major subtypes of driver mutations that have been identified in NSCLC and relevant targeted therapies available both now, and in the foreseeable future. (amegroups.org)
Cases2
- Around 90% of NSCLC cases are associated with active cigarette smoking [ 1 ]. (biomedcentral.com)
- [ 3 , 4 ] The term "pseudomesotheliomatous carcinoma" was first applied by Harwood and colleagues in 1976 to 6 cases of peripheral lung adenocarcinoma that closely mimicked mesothelioma. (medscape.com)
Accounts1
- The most common histologic subtype is adenocarcinoma (ADC), which accounts for approximately 50% of NSCLCs ( 3 , 4 ). (amegroups.org)
Types1
- As compared to the previous edition, changes include a better definition of pre-invasive lesion, a reclassification of adenocarcinoma, the description of two new tumour types as variants of large cell carcinoma, large cell neuroendocrine carcinoma (LCNEC) and basaloid carcinoma, and a new class called pleomorphic carcinoma. (ersjournals.com)
Risk1
- Cigarette smoking is a strong risk factor for developing non-small cell lung cancer (NSCLC). (biomedcentral.com)
Standard1
- Whilst empirical chemotherapy with a platinum-doublet remains the gold standard for advanced NSCLC without a known driver mutation, targeted therapy is pushing the boundary to significantly improve patient outcomes and quality of life. (amegroups.org)
Figure1
- The traditional and now over-simplified histological distinctions within NSCLC include adenocarcinoma, SCC and large cell carcinoma ( Figure 1 ). (amegroups.org)
Years1
- In recent years, there has been a major paradigm shift in the management of non-small cell lung cancer (NSCLC). (amegroups.org)
Predominant histological1
- Non-small-cell lung cancer (NSCLC) is the predominant histological subtype of LC, accounting for 76% of LC. (biomedcentral.com)
Squamous cell carcinomas3
- However, recent biological data suggest that different NSCLC subtypes, specifically adenocarcinomas (AC) and squamous cell carcinomas (SCC), differentially alter cancer behavior. (nih.gov)
- Adenocarcinomas: EGFR Mutations K-ras Mutations EML4-ALK Fusions and Mutations Signet ring cell Acinar Papillary Micropapillary Squamous cell carcinomas: Small cell, poorly differentiated Basaloid Large cell carcinomas: Undifferentiated Lymphoepithelioma-like Rhabdoid phenotype Other NSCLC's: Clear cell variants Giant cell carcinomas HOHMS applied to certain lung cancer variants Undifferentiated large cell lung cancer has been shown to be particularly responsive to pemetrexed. (wikipedia.org)
- Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. (nih.gov)
Cancers5
- Among on the lung cancers, NSCLC is about 80% and mainly constitutes lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC)[2]. (researchsquare.com)
- EML4-ALK (+) lung cancers Acinar predominant adenocarcinoma and crizotinib Signet ring cell adenocarcinoma and crizotinib Papillary adenocarcinoma BAC with EGFR (+) Squamous cell carcinoma (cisplatinum/gemcitabine) Squamous cell carcinoma (no bevacizumab/anti-VEGF in cavitary or in near large vessels Vincent MD (August 2009). (wikipedia.org)
- Locations of lung cancers depicted are generalized sites typical of lung tumorigenesis for subtypes. (biomedcentral.com)
- Lung cancers are classified into two major types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). (biomedcentral.com)
- NSCLC accounts for ∼ 85% of all lung cancers and has multiple histological subtypes including adenocarcinoma and central squamous cell carcinoma . (amboss.com)
Large cell carcinoma2
- The three major histological subtypes of NSCLC are adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large cell carcinoma (LCC) (Fig. 1 ). (biomedcentral.com)
- As a heterogeneous disease, NSCLC is further subdivided into three major subtypes: squamous cell carcinoma (SqCC), large cell carcinoma (LCC) and adenocarcinoma (AC). (biomedcentral.com)
Carcinomas2
- In the last two decades, however, the development of molecularly targeted agents have led to an increased emphasis on more precise typing and subtyping of lung carcinomas. (wikipedia.org)
- Percentage distributions of NSCLC histologies total to NSCLC percentage (83.4 %), where remaining histogies (non-small cell carcinoma and other specified carcinomas) are not depicted. (biomedcentral.com)
Heterogeneous1
- This "traditional" paradigm, wherein treatment options for lung cancer patients were based on histological stratification into two highly heterogeneous groups (i.e. (wikipedia.org)
Tumors2
- Although the 2015 World Health Organization (WHO) Classification of lung tumors reported that histological grading may be helpful for lung cancer management ( 7 ), a widely accepted histological grading system with clearly defined criteria and demonstrable clinical significance has not yet been developed for lung cancer, and more evidence than presented in the WHO report is needed ( 8 ). (iiarjournals.org)
- Our laboratory has translated (NCT02414269, NCT02792114) mesothelin (MSLN), a cancer-antigen, targeted chimeric antigen receptor (CAR) T-cell therapy to solid tumors including for lung adenocarcinoma (ADC) patients. (iaslc.org)
Biomarkers4
- In order to detect NSCLC and determine its prognosis, practical and accurate biomarkers for NSCLC must be identified ( 5 , 6 ). (iiarjournals.org)
- We used microarray gene expression dataset GSE10245 to identify key biomarkers and associated pathways in NSCLC. (springeropen.com)
- In this investigation, we aimed to identify molecular biomarkers for NSCLC using microarray technology, which may help its early diagnosis and prognosis. (springeropen.com)
- The goal of this investigation is to identify molecular biomarkers, to make potential therapeutic medicine for future NSCLC treatment. (springeropen.com)
Unclear2
- Although previous studies have demonstrated that stage I lung adenocarcinoma can be prognostically stratified using architectural patterns, the prognostic value of architectural subtypes in more advanced stages of lung adenocarcinoma remains unclear ( 13 ). (iiarjournals.org)
- However, the functional significance of UCH-L1 in the progression of NSCLC is unclear. (biomedcentral.com)
Genes1
- In this study, we collected microarray dataset GSE10245 from the Gene Expression Omnibus (GEO) database and utilized R language to identify the differentially expressed genes (DEGs) between adenocarcinoma and SCC. (springeropen.com)
Incidence2
- Percent incidence and typical histologies of lung cancer subtypes. (biomedcentral.com)
- In this overview we discuss the steeper increase during recent decades of lung adenocarcinoma incidence compared with squamous cell carcinoma of the lung. (nih.gov)
Methods1
- We apply both methods to the same dataset to assess their implications among early-stage NSCLC. (iaslc.org)
Mortality1
- Non-small-cell lung cancer (NSCLC) is the most common cause of cancer-related mortality. (nih.gov)
Therapeutic1
- Therefore, the development of a novel therapeutic drug for NSCLC is urgently needed. (oatext.com)
Outcomes1
- Outcomes indicate that Stratifin may play a crucial role in the development of NSCLC. (springeropen.com)
Progression1
- NSCLC has a poor prognosis because of its rapid progression and lack of early-stage symptoms ( 4 ). (iiarjournals.org)
Metastasis2
- UBE2V2 promotes metastasis by regulating EMT and predicts a poor prognosis in lung adenocarcinoma. (researchsquare.com)
- Although UCH-L1 appears to be involved in carcinogenic processes in NSCLC cell lines, the absence of correlation with patient survival indicates that caution is required in the use of UCH-L1 as a potential prognostic marker for advanced stage and metastasis in lung carcinoma. (biomedcentral.com)
Invasion2
- Multivariate analysis identified histological grade and vascular invasion as independent predictors of OS [histological grade: HR=1.533, p=0.002]. (iiarjournals.org)
- This suggests UCH-L1 may be involved in oncogenic transformation and tumour invasion in NSCLC. (biomedcentral.com)
Carcinogens1
- Under these conditions, the peripheral lung is exposed to increased amounts of smoke carcinogens that are suspected to lead to lung adenocarcinoma. (nih.gov)
Significantly3
- The miR-301a and miR-301b were significantly upregulated in NSCLC tissues compared to those in matched-pair adjacent normal lung tissues. (oatext.com)
- BSO treatment also significantly potentiated cisplatin-induced cytotoxicity in mesothelioma and adenocarcinoma cells. (charismaticplanet.com)
- Three factors were significantly associated with an increased probability of developing cystic lesions: age at diagnosis ≤ 40 years, age at BM ≤ 45 years, and poor histological grade ( p (oncotarget.com)
Cells6
- Overexpression of miR-301a/b promoted cell proliferation and miR-301b further promoted migration ability in NSCLC cells. (oatext.com)
- Expression of UCH-L1 was decreased by siRNA in both cell lines, resulting in increased cell death in H838 adenocarcinoma cells but not in the H157 squamous cell line. (biomedcentral.com)
- In contrast to mesothelioma cells, lung A549 adenocarcinoma cells, which represent an oxidant and drug-resistant cell line, contained similar levels of MnSOD as non-malignant mesothelial cells. (charismaticplanet.com)
- GST could not explain the resistance of adenocarcinoma cells. (charismaticplanet.com)
- Is the activity of total GST lower in adenocarcinoma cells than in more sensitive mesothelioma cells? (charismaticplanet.com)
- The role of GSH and catalase were also investigated by treating the Malignant Pleural Mesothelioma cells and A549 adenocarcinoma cells with buthionine sulfoximine (BSO), to block glutathione synthesis, and aminotriazole (ATZ) to inhibit catalase. (charismaticplanet.com)
Small3
- Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. (nih.gov)
- Traditionally, non-small cell lung cancer (NSCLC) has been evaluated as a unique entity in genotyping studies. (nih.gov)
- Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer death worldwide. (oatext.com)
Stage1
- The aim of this study was to investigate the role of UCH-L1 using NSCLC cell line models and to determine if it is clinically relevant as a prognostic marker for advanced stage disease. (biomedcentral.com)
Study1
- In 2011, the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society (IASLC/ATS/ERS) proposed a new classification of lung adenocarcinoma based simply on histological subtypes ( 9 ). (iiarjournals.org)
Approximately1
- approximately 40% of NSCLC is adenocarcinoma. (springeropen.com)
Expression1
- UCH-L1 expression in NSCLC cell lines H838 and H157 was modulated by siRNA-knockdown, and the phenotypic changes were assessed by flow cytometry, haematoxylin & eosin (H&E) staining and poly (ADP-ribose) polymerase (PARP) cleavage. (biomedcentral.com)
System1
- Background/Aim: Although the 2015 World Health Organization Classification reported that histological grading may be helpful in lung cancer management, a widely accepted histological grading system with clearly defined criteria and demonstrable clinical significance has not been developed. (iiarjournals.org)
Disease1
- A complete staging workup for NSCLC should be carried out to evaluate the extent of disease. (medscape.com)